Gedea och Akuro i topp
12 september 2018 I onsdags kom Gedea Biotech på en delad förstaplats och Akuru Pharma på en tredjeplats i pitchtävlingen ” Startup Challenge” vid NLSDays, Nordens största partneringmässa inom life science. Det är andra året i rad som SmiLe-bolag tar topplaceringar i tävlingen. Läs hela…
Gedea in Serendipity Challenge final in Almedalen
Gedea Biotech has reached the finals in Serendipity Challenge that is an annual entrepreneurship competition and tech venue open to all Swedish and Nordic startups and growth companies. The competition final takes place during Almedalsveckan (2-4 July) where 50 of the most innovative and promising…
The antimicrobial resistance issue requires many small solutions
Today, Rapidus draws attention to the problem of antimicrobial resistance and the challenge of more and more antibiotics becoming ineffective. Gedea Biotech's forthcoming treatment is mentioned as a solution, among others, which will make us less dependent on antibiotics. Read full article
Gedea Biotech has received 1 MSEK for clinical study for CE mark of new product
Smile Company Gedea Biotech has received 1 MSEK in Vinnova funding in Swelife and MedTech4Health's joint announcement "Project for better health". The money will finance the first clinical trial in patients with vaginal fungal infection. Read more
CEO on Rapidus´list over talent from Skåne
Rapidus made a list of talented young professionals in the business environment in Skåne "that Stockholm based media missed". On the list is Annette Säfholm, CEO of Gedea Biotech. Read full article here.
Gedea Biotech receives Vinnova financing and strengthens the board
Gedea Biotech has been granted 900.000 SEK in Vinnova's grant program for innovative startup companies. The company has also expanded the board with Mats Persson, who has over 30 years of experience in marketing and sales in life sciences. The recruitment means a valuable strengthening of the…
Successful capital raising for Gedea Biotech
Gedea Biotech has raised 11 MSEK for clinical trials throughout 2018, to verify the treatment of vaginal infections. The share issue has attracted a large interest from investors and was expanded from estimated 7 MSEK to 11 MSEK. Read more
Gedea Biotech was the audience's choice in Venture Cup's Sweden final
When the 15 finalists pitched their business ideas, the audience voted to choose their favorite in Thursday's Sweden final in the Venture cup entrepreneurship competition. Gedea Biotech, received the most votes, thereby winning the Venture Cup Crowd Award, and free business trips by train in first…
Gedea Biotech in Venture Cup's Sweden final, winner to be announced today!
Gedea Biotech is one of 15 finalists in the national Venture cup final in Lund on September 21. The company advanced after winning Southern Sweden's semifinal in the "Game changer" class. Gedea Biotech, which develops an antibiotic-free, local treatment with a completely new mode of action for the…
Kemivärlden Biotech recognizes Gedea Biotech in article
The magazine Kemivärlden Biotech recently published an article about Gedea Biotech, where chairman Olov Sterner describes the driving force to find a treatment of vaginal infections which is not based on antibiotics to get around the resistance problem. The article also describes the company's…